Skip to main content
. 2024 Mar 8;14(5):846–865. doi: 10.1158/2159-8290.CD-23-0388

Figure 6.

Figure 6. Capivasertib (AZD5363) plus AZD5991 combination activity in endometrial cell lines. A, Screening results of combo Emax versus HSA in endometrial cell lines treated with AZD5363 plus AZD5991. Cell lines with high combination activity are in red. B, Representative growth inhibition and HSA excess matrix plots in endometrial AN3CA cells. C, Matrix plot measuring apoptosis with AZD5991 and AZD5363 at indicated doses for 6 hours in AN3-CA cells. D, Matrix plots showing viability for AN3-CA cells pretreated with DMSO or QVD (caspase inhibitor) for 16 hours prior to the combination for 6 hours. E, Western blot analysis in AN3-CA cells treated with AZD5363 (1 μmol/L), AZD5991 (500 nmol/L), or in combination at indicated times. F, Matrix plots showing viability in AN3-CA cells treated with AZD5991 or venetoclax (ABT-199 -BCL2 inhibitor), AZD4320 or AZ3202 (BCL-XL inhibitors) with AZD5363 at indicated doses for 6 hours.

Capivasertib (AZD5363) plus AZD5991 combination activity in endometrial cell lines. A, Screening results of combo Emax versus HSA in endometrial cell lines treated with AZD5363 plus AZD5991. Cell lines with high combination activity are in red. B, Representative growth inhibition and HSA excess matrix plots in endometrial AN3CA cells. C, Matrix plot measuring apoptosis with AZD5991 and AZD5363 at indicated doses for 6 hours in AN3-CA cells. D, Matrix plots showing viability for AN3-CA cells pretreated with DMSO or QVD (caspase inhibitor) for 16 hours prior to the combination for 6 hours. E, Western blot analysis in AN3-CA cells treated with AZD5363 (1 μmol/L), AZD5991 (500 nmol/L), or in combination at indicated times. F, Matrix plots showing viability in AN3-CA cells treated with AZD5991 or venetoclax (ABT-199 -BCL2 inhibitor), AZD4320 or AZ3202 (BCL-XL inhibitors) with AZD5363 at indicated doses for 6 hours.